A detailed history of Pathstone Holdings, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Pathstone Holdings, LLC holds 12,500 shares of EXEL stock, worth $439,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,500
Previous 12,016 4.03%
Holding current value
$439,875
Previous $269,000 20.45%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$21.96 - $27.6 $10,628 - $13,358
484 Added 4.03%
12,500 $324,000
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $41,941 - $48,931
2,062 Added 20.72%
12,016 $269,000
Q1 2024

May 13, 2024

BUY
$20.17 - $23.93 $23,659 - $28,069
1,173 Added 13.36%
9,954 $236,000
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $169,034 - $211,885
8,781 New
8,781 $210,000

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.3B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.